Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: saito r. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K. Sakai K, et al. Among authors: saito r. Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1. Cancer Sci. 2013. PMID: 23721103 Free PMC article.
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T. Inoue A, et al. Among authors: saito r. Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4. Lung Cancer. 2015. PMID: 26004087 Clinical Trial.
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
Nakamura A, Tanaka H, Saito R, Suzuki A, Harada T, Inoue S, Yamada T, Nakagawa T, Jingu D, Sugawara S. Nakamura A, et al. Among authors: saito r. Oncologist. 2020 Oct;25(10):e1451-e1456. doi: 10.1634/theoncologist.2020-0545. Epub 2020 Jul 7. Oncologist. 2020. PMID: 32559335 Free PMC article. Clinical Trial.
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. Tanaka H, et al. Among authors: saito r. Thorac Cancer. 2021 Jul;12(14):2113-2121. doi: 10.1111/1759-7714.14048. Epub 2021 Jun 2. Thorac Cancer. 2021. PMID: 34076966 Free PMC article. Clinical Trial.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: saito r. Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13. Int J Clin Oncol. 2022. PMID: 34643820 Free PMC article. Clinical Trial.
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Oizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: saito r. Int J Clin Oncol. 2022 Apr;27(4):823-824. doi: 10.1007/s10147-022-02118-8. Int J Clin Oncol. 2022. PMID: 35257278 Free PMC article. No abstract available.
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Suzuki Y, Takeda K, Miyauchi E, Saito R, Katsuta Y, Kadoya N, Jingu K. Yamamoto T, et al. Among authors: saito r. BMC Cancer. 2022 Apr 4;22(1):364. doi: 10.1186/s12885-022-09354-1. BMC Cancer. 2022. PMID: 35379201 Free PMC article.
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Tsubata Y, Kawakado K, Hamai K, Furuya N, Yokoyama T, Saito R, Nakamura A, Masuda T, Hamaguchi M, Kuyama S, Honda R, Senoo T, Nakanishi M, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: saito r. Int J Clin Oncol. 2023 Jan;28(1):69-78. doi: 10.1007/s10147-022-02257-y. Epub 2022 Nov 10. Int J Clin Oncol. 2023. PMID: 36357710 Free PMC article.
2,139 results